Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Human rotavirus" patented technology

Single-domain antibody to reduce the risk of rotavirus a infection

A single-domain antibody (sdAb) which binds to head domain of VP6 derived from a human rotavirus A and has neutralization activity against different the rotavirus A types.
Owner:BACTOLIFE AS

G8P [8] type A rotavirus CZ-23 and application thereof

The invention relates to the technical field of rotaviruses, in particular to a G8P [8] type group A rotavirus CZ-23 and application thereof. The invention relates to a G8P [8] type group A rotavirus CZ-23, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 11, 2023, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides a novel human rotavirus wild strain which is reported and separated for the first time in China, and the strain is strong in virus replication capability and good in hereditary stability, can be applied to development of vaccine strains of human rotavirus vaccines, and is suitable for attenuated rotavirus oral vaccines.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

A human-ovine rotavirus recombinant plasmid, a human-ovine rotavirus reassortant virus strain, and a construction method and application thereof

The present invention provides a human-ovine rotavirus recombinant plasmid, a human-ovine rotavirus reassortant virus strain, and a construction method and application thereof, belonging to the technical field of rotavirus vaccines. The sequences of 8 human rotavirus infectious clone plasmids of the present invention are respectively shown as SEQ ID NO:1 to SEQ ID NO:8. By using the above 8 human rotavirus plasmids and 11 ovine rotavirus infectious clone plasmids, 8 human-ovine rotavirus reassortant strains were successfully prepared through a reverse genetics virus rescue system, filling the gap that the main antigens of existing rotavirus vaccine strains in China do not match the main epidemic strains in China.
Owner:INOWELLCOME (BEIJING) BIOTECHNOLOGY CO LTD

Circular RNA (Ribonucleic Acid) molecule and application thereof in resisting rotavirus replication

The invention belongs to the technical field of medical biology, and particularly relates to a circular RNA (Ribonucleic Acid) molecule and an application thereof in resisting rotavirus replication, and provides the circular RNA molecule of which the nucleotide sequence is shown as SEQ ID No.1. Through a high-throughput sequencing technology, a human rotavirus wild strain obtained by separation is infected with a host cell and then is subjected to complete transcription sequencing, so that a high-throughput sequencing result is obtained. A brand-new circular RNA molecule circRNA46 for regulating and controlling rotavirus proliferation is found, the nucleotide sequence of the circular RNA molecule circRNA46 is shown as SEQ ID No.1, the circRNA46 is up-regulated after virus infection, overexpression of the circRNA46 can obviously inhibit virus replication, and the circRNA46 has the effect of resisting rotavirus proliferation.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Recombinant human rotavirus vaccine and preparation method thereof

The invention discloses a recombinant human rotavirus vaccine and a preparation method thereof, and relates to the technical field of vaccines, the vaccine comprises: (1) antigens: 25-65 [mu] g of P [4] type antigen, 25-65 [mu] g of P [6] type antigen and 25-65 [mu] g of P [8] type antigen, and the amino acid sequences of the P [4] type antigen, the P [6] type antigen and the P [8] type antigen are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; the active component of each type of antigen is a recombinant rotavirus VP8 fusion protein, the recombinant rotavirus VP8 fusion protein is composed of a first polypeptide, a second polypeptide and a third polypeptide, the first polypeptide is a truncated human rotavirus VP8 protein, the second polypeptide is a truncated human rotavirus VP8 protein, and the third polypeptide is a truncated human rotavirus VP8 protein. The second polypeptide is an Fc fragment amino acid sequence of immunoglobulin IgG4; the third polypeptide is not charged or negatively charged; (2) an adjuvant: 4.0 mg to 6.0 mg of an aluminum hydroxide adjuvant; and (3) buffer solution: sodium chloride and HEPES solution. The recombinant human rotavirus vaccine is effective and safe.
Owner:四川明瑞佳生物科技有限公司